KRAS and non-small cell lung carcinoma: We evaluated 219 patients with single punctiform mutation on KRAS G12 treated in four Italian oncology units with CT or immune checkpoint inhibitors (ICIs) alone or their combination as first-line therapy for stage IV NSCLC.